Clinical Trial Update: Radium 223 Following Intermittent ADT [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Radium-223 following intermittent androgen deprivation therapy for prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Radium-223 dichloride (Xofigo) (radium-223 dichloride)

Snippet

Sponsor: Canadian Urology Research Consortium | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN